Silence Therapeutics (SLN) Assets Average (2019 - 2025)
Historic Assets Average for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $156.0 million.
- Silence Therapeutics' Assets Average fell 7982.24% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.0 million, marking a year-over-year decrease of 7982.24%. This contributed to the annual value of $161.0 million for FY2024, which is 2756.22% up from last year.
- As of Q3 2025, Silence Therapeutics' Assets Average stood at $156.0 million, which was down 7982.24% from $175.3 million recorded in Q2 2025.
- Silence Therapeutics' Assets Average's 5-year high stood at $773.2 million during Q3 2024, with a 5-year trough of $156.0 million in Q3 2025.
- In the last 5 years, Silence Therapeutics' Assets Average had a median value of $476.0 million in 2023 and averaged $417.9 million.
- Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 8886.44% in 2022, then tumbled by 7982.24% in 2025.
- Silence Therapeutics' Assets Average (Quarter) stood at $262.4 million in 2021, then soared by 88.86% to $495.5 million in 2022, then dropped by 3.94% to $476.0 million in 2023, then grew by 7.54% to $511.9 million in 2024, then tumbled by 69.52% to $156.0 million in 2025.
- Its Assets Average was $156.0 million in Q3 2025, compared to $175.3 million in Q2 2025 and $194.0 million in Q1 2025.